ELVN (Enliven Therapeutics Inc) רווח למניה בארבעת הרבעונים האחרונים

The EPS YoY TTM shift metric on GURU.Markets demonstrates profit dynamics, where 8.00 is the current value of the indicator. Enliven Therapeutics (ELVN) relies on solid capital, which ensures balance sheet stability. However, a narrow specialization in small molecules creates risks due to dependence on testing. In a fierce race for molecular precision, the success of third-party developments could become a critical challenge.
Enliven Therapeutics Inc - פילוחים אנליטיים ומדדי מפתח (ELVN)

EPS TTM dynamics reflect the rate of change in net income per share over the year, allowing investors to assess value generation efficiency and business model sustainability. For the pre-commercial developer Enliven Therapeutics (ELVN), where R&D cost growth outpaces revenues, measuring the annual EPS TTM growth reveals a lack of operating leverage, confirming the high capital intensity of the clinical trial stage.